Biography

Dr. M. Shaalan Beg joined the Division of Hematology/Medical Oncology specializing in cancers of the gastrointestinal tract. After receiving his medical training at the Aga Khan University in Karachi, Pakistan, he proceeded to complete his Internal Medicine residency and Hematology/Medical Oncology fellowship at the University of Cincinnati.

Dr. Beg’s clinical and research focus is on early-phase drug development and clinical trials for gastrointestinal cancers. He is an active member of the GI Cancers Disease Oriented Team and believes in true multidisciplinary care of his patients.

Education

Medical School
Aga Khan Univ, Pakistan (2003)
Residency
University of Cincinnati College of Medicine (2008), Internal Medicine
Fellowship
University of Cincinnati (2011), Hematology Oncology

Research Interest

  • Cancers of the gastrointestinal tract
  • Decentralized clinical trials
  • Digital Health
  • Early phase drug development, Phase I/II clinical trials
  • Experimental therapeutics

Publications

Featured Publications LegendFeatured Publications

Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer.
Bhulani N, Gupta A, Gao A, Li J, Guenther C, Ahn C, Paulk E, Houck S, Beg MS J Gastrointest Oncol 2018 Jun 9 3 495-502
Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications.
Hosein AN, Beg MS Curr Oncol Rep 2018 May 20 7 56
Trends in Outcomes of Patients With Metastatic Cancer Undergoing Intubation and Mechanical Ventilation: Results of the National Hospital Discharge Survey.
Gupta A, Das A, Tariq R, Bhulani N, Premnath N, Solanky D, Frank RD, Johnson D, Khanna S, Beg MS J Natl Compr Canc Netw 2018 Mar 16 3 286-292
Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers.
Beg MS, Meyer J J Gastrointest Oncol 2018 Feb 9 1 225-230
Approach and management of checkpoint inhibitor-related immune hepatitis.
Sanjeevaiah A, Kerr T, Beg MS J Gastrointest Oncol 2018 Feb 9 1 220-224
Pasireotide for the Treatment of Refractory Hypoglycemia from Malignant Insulinoma.
Hendren NS, Panach K, Brown TJ, Peng L, Beg MS, Weissler J, Mirfakhraee S Clin. Endocrinol. (Oxf) 2017 Oct
The NQO1 bioactivatable drug, ß-Lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA, Deja S, Singh N, Egnatchik RA, Sudderth J, Luo X, Beg MS, Burgess SC, DeBerardinis RJ, Boothman DA, Merritt ME J. Biol. Chem. 2017 Sep
Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus.
Arora N, Gupta A, Zhu H, Christie A, Meyer JJ, Khan SA, Beg MS J Natl Compr Canc Netw 2017 Aug 15 8 998-1004
Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality: A Systematic Review and Meta-Analysis.
Gupta A, Das A, Majumder K, Arora N, Mayo HG, Singh PP, Beg MS, Singh S Am. J. Clin. Oncol. 2017 May
Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Clostridium difficile Infection: A Nationwide Analysis.
Gupta A, Tariq R, Frank RD, Jean GW, Beg MS, Pardi DS, Johnson DH, Khanna S J Natl Compr Canc Netw 2017 Apr 15 4 466-472

Honors & Awards

  • ASCO Leadership Development Program
    (2019)
  • Principal Investigator, NCI Experimental Therapeutics Clinical Trials Network (ETCTN) UM1 Award
    (2019)
  • ASCO Quality Training Program
    (2017)
  • Chair, Pancreatic-Hepatobiliary Working Group, GI Cancer Core Committee, ECOG/ACRIN
    (2017)
  • Pancreatic Cancer Task Force, GI Cancer Steering Committee, National Cancer Institute
    (2017)
  • D Magazine, Best Doctors
    (2016)
  • Resident Teacher Award
    University of Cincinnati

Professional Associations/Affiliations

  • ECOG/ACRIN Research Group (2014)
  • American Society of Clinical Oncology (2008)